by adminmps | Jun 30, 2022 | News
The Canadian MPS Society welcomes the news that the Government of Quebec has unveiled its policy for rare diseases which affect approximately 700,000 people in the province in order to improve the accessibility of health care and services adapted to the needs of...
by adminmps | Jun 17, 2022 | Clinical Trials, News, Research
Lysogene has just provided promising data from their clinical trials for the efficacy of Gene Therapy LYS-SAF302 in the treatment of MPS IIIA. Read Press Release >
by adminmps | Jun 17, 2022 | News, Resources
Titus and his family have made a series of videos to show what it’s like to grow up with Morquio (MPS IV). Find out more about Morquio Syndrome...
by adminmps | Jun 17, 2022 | News, Resources
Saving Ryan is the inspiring story by physician-scientist Dr. Emil Kakkis about his journey to develop a new, first-ever treatment for MPS. Hear about the great challenges getting grant and industry support for this rare disease despite the solid science behind doing...
by adminmps | May 26, 2022 | Clinical Trials, News, Research
The Canadian MPS Society met directly with Takeda Pharmaceuticals on May 11th, when Takeda shared with us that they will discontinue development of TAK-609, investigational intrathecal enzyme replacement therapy for MPS II, Hunter syndrome. Patients with MPS II...
